Proxygen Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Molecular Glue Degraders
05 avr. 2023 07h00 HE
|
Proxygen
VIENNA, Austria, April 05, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research collaboration and license...
Cell Dissociation Market is estimated to be US$ 1097.1 Million by 2032 with a CAGR of 14.2% over the forecast period (2022-2032) - By PMI
05 janv. 2023 09h32 HE
|
PMI
Covina, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The process of cell dissociation, also known as trypsinization, involves a proteolytic enzyme that helps break down proteins to separate adherent cells from...
Bioreactors Market is estimated to be US$ 9.5 billion by 2032 with a CAGR of 7.2% over the forecast period (2022-2032) - By PMI
02 janv. 2023 09h05 HE
|
PMI
Covina, Jan. 02, 2023 (GLOBE NEWSWIRE) -- Bioreactors Market are used in production of vaccines, cell therapies, gene therapies and therapeutics. Different types of Bioreactors Markets are used for...
Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab)
11 oct. 2022 08h00 HE
|
Compass Therapeutics
BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury
03 févr. 2022 07h30 HE
|
Arch Biopartners
TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Daniel Muruve at...
The Alliance for Advancing Health Online Invests $7M+ through the Vaccine Confidence Fund to Boost Vaccination Confidence through Social Media
14 oct. 2021 12h33 HE
|
Global Impact
ALEXANDRIA, VA, Oct. 14, 2021 (GLOBE NEWSWIRE) -- The Vaccine Confidence Fund (VCF) is pleased to announce the selection of 33 organizations that will receive grants totaling over $7 million from...
ACCELERON PHARMA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of XLRN and Encourages Investors to Contact the Firm
01 oct. 2021 11h54 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA
04 août 2021 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease
14 juil. 2021 07h00 HE
|
Arch Biopartners
TORONTO, July 14, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury
15 avr. 2021 07h00 HE
|
Arch Biopartners
Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammationNovel Mechanism of Action - selective dipeptidase-1 (DPEP-1) antagonists...